Prospective Pathology Foundation Models

ConditionPancancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorNanfang Hospital, Southern Medical University

About this trial

Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.

Eligibility criteria

Qualifiers

Aged 18-75 years old.

Patients with complete pathological slides and clinical information.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Nanfang Hospital, Southern Medical University

Lead sponsor

Qianfoshan Hospital

Collaborator

Zhejiang University

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

First Affiliated Hospital of Shantou University Medical College

Collaborator

Zhujiang Hospital

Collaborator

Air Force Military Medical University, China

Collaborator